Targeting metabolic transformation for cancer therapy

被引：906

作者：

Tennant, Daniel A. ^{[1
]}

Duran, Raul V. ^{[2
]}

Gottlieb, Eyal ^{[1
]}

机构：

[1] Beatson Inst Canc Res, Canc Res UK, Glasgow G61 1BD, Lanark, Scotland

[2] Univ Basel, Growth & Dev Biozentrum, Basel, Switzerland

来源：

NATURE REVIEWS CANCER | 2010年 / 10卷 / 04期

关键词：

FATTY-ACID SYNTHASE; TUMOR-CELL GROWTH; RECURRENT GLIOBLASTOMA-MULTIFORME; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CARBONIC-ANHYDRASE INHIBITORS; BREAST-CARCINOMA CELLS; PHASE-II TRIAL; PYRUVATE-KINASE; TEMSIROLIMUS CCI-779; KETOGENIC DIET;

D O I：

10.1038/nrc2817

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer therapy has long relied on the rapid proliferation of tumour cells for effective treatment. However, the lack of specificity in this approach often leads to undesirable side effects. Many reports have described various 'metabolic transformation' events that enable cancer cells to survive, suggesting that metabolic pathways might be good targets. There are currently several drugs under development or in clinical trials that are based on specifically targeting the altered metabolic pathways of tumours. This Review highlights pathways against which there are already drugs in different stages of development and also discusses additional druggable targets.

引用

页码：267 / 277

页数：11

共 154 条

[61] Tumours with PI3K activation are resistant to dietary restriction [J].

Kalaany, Nada Y. ;

Sabatini, David M. .

NATURE, 2009, 458 (7239) :725-U61

[62] HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia [J].

Kim, JW ;

Tchernyshyov, I ;

Semenza, GL ;

Dang, CV .

CELL METABOLISM, 2006, 3 (03) :177-185

[63] Glucose metabolism and programmed cell death: an evolutionary and mechanistic perspective [J].

King, Ayala ;

Gottlieb, Eyal .

CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (06) :885-893

[64] Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP [J].

Ko, YH ;

Smith, BL ;

Wang, YC ;

Pomper, MG ;

Rini, DA ;

Torbenson, MS ;

Hullihen, J ;

Pedersen, PL .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (01) :269-275

[65] Phloretin-induced apoptosis in B16 melanoma 4A5 cells by inhibition of glucose transmembrane transport [J].

Kobori, M ;

Shinmoto, H ;

Tsushida, T ;

Shinohara, K .

CANCER LETTERS, 1997, 119 (02) :207-212

[66] Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α [J].

Koh, Mei Y. ;

Spivak-Kroizman, Taly ;

Venturini, Sara ;

Welsh, Sarah ;

Williams, Ryan R. ;

Kirkpatrick, D. Lynn ;

Powis, Garth .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) :90-100

[67]

Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.CAN-03-3645

[68]

LANDAU BR, 1958, JNCI-J NATL CANCER I, V21, P485

[69] Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted [J].

Langbein, S ;

Zerilli, M ;

zur Hausen, A ;

Staiger, W ;

Rensch-Boschert, K ;

Lukan, N ;

Popa, J ;

Ternullo, MP ;

Steidler, A ;

Weiss, C ;

Grobholz, R ;

Willeke, F ;

Alken, P ;

Stassi, G ;

Schubert, P ;

Coy, JF .

BRITISH JOURNAL OF CANCER, 2006, 94 (04) :578-585

[70] RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization (Retracted Article) [J].

Lee, KangAe ;

Zhang, Huafeng ;

Qian, David Z. ;

Rey, Sergio ;

Liu, Jun O. ;

Semenza, Gregg L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (42) :17910-17915

← 2 3 4 5 6 7 8 9 10 11 →